Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 80 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: In Vitro diagnostic tests Clear all

Conditions: Lyme Disease
Interventions: Borrelia Diagnostic Test; Device
Lead sponsor: Advanced Laboratory Services, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Georgetown, Delaware • Rockport, Maine • Springfield, Massachusetts + 13 more

Conditions: Covid19
Interventions: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test; Diagnostic Test
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Vitamin D Deficiency, Vitamin D Insufficiency, Healthy Volunteers
Interventions: ALPCO 25(OH) Vitamin D CLIA Kit; Device
Lead sponsor: American Laboratory Products Company; Industry
Eligibility: 22 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salem, New Hampshire

Conditions: Chronic Lymphoproliferative Diseases (CLPD)
Interventions: IUO CLPD Limited Panel; Diagnostic Test
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 22 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • San Antonio, Texas

Conditions: Hematology, Hematologic Test
Interventions: Hematology Analyzer - OLO, Hematology Analyzer - Predicate; Device
Lead sponsor: Sight Diagnostics; Industry
Eligibility: 3 Months and older
Enrollment: 679 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aneuploidy, Down Syndrome, Noninvasive Prenatal Screening
Interventions: SEQureDx Trisomy Test; Device
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 3,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Breast Cancer
Interventions: Nanomechanical Phenotype Test; Diagnostic Test
Lead sponsor: ARTIDIS AG; Industry
Eligibility: 18 Years and older
Enrollment: 2,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Seattle, Washington

Conditions: Plasma Cell Disorder
Interventions: IUO Plasma Cell Disorders Panel; Diagnostic Test
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 22 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chlamydia Infections, Gonorrhea, Trichomonas Infections
Interventions: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays; Device
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • North Miami, Florida + 11 more

Conditions: Lyme Disease
Interventions: T2Lyme Panel testing; Device
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wakefield, Rhode Island • La Crosse, Wisconsin

Conditions: Acute Infection
Interventions: MeMed BV; Diagnostic Test
Lead sponsor: MeMed Diagnostics Ltd.; Industry
Eligibility: 90 Days and older
Enrollment: 1,384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 5 more

Conditions: Breast Neoplasms, Breast Diseases
Interventions: OSNA Breast Cancer System; Device
Lead sponsor: Sysmex America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Santa Monica, California • Marietta, Georgia • St Louis, Missouri + 8 more

Conditions: Breast Cancer
Interventions: GeneSearch™ Breast Lymph Node (BLN) Assay; Device
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: COVID-19 Pandemic
Interventions: In Vitro; Diagnostic Test
Lead sponsor: 3EO Health; Industry
Eligibility: 2 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Sunrise, Florida + 2 more

Conditions: Diabetes, Hypertension
Interventions: ACR LAB; Device
Lead sponsor: Healthy.io Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Atlanta, Georgia • Lexington, Kentucky • Garden City, New York

Conditions: Bacterial Vaginosis, Candida Vaginitis
Interventions: cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay; Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 738 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more

Conditions: Leukemia
Interventions: aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, in vitro treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 2 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Infertility, Female, Endometriosis
Interventions: Endometrial Biopsy, Euploid embryo transfer, Blood sample; Procedure · Other · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more

Conditions: Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
Interventions: EXoPred; Diagnostic Test
Lead sponsor: EXoPERT; Industry
Eligibility: 45 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Long Beach, California • Los Angeles, California • Honolulu, Hawaii + 6 more

Conditions: Muscle-Invasive Bladder Carcinoma
Interventions: C2i Test; Diagnostic Test
Lead sponsor: C2i Genomics; Industry
Eligibility: 22 Years to 100 Years
Enrollment: 3 participants
Timeline: 2022
U.S. locations: 1
States / cities: Bloomfield, New Jersey

Conditions: Oral Squamous Cell Carcinoma
Interventions: saliva collection prior to clinically driven oral biopsy; Other
Lead sponsor: PeriRx; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Ann Arbor, Michigan • East Lansing, Michigan + 2 more

Conditions: Bladder Cancer
Interventions: Xpert Bladder Cancer Monitor; Device
Lead sponsor: Cepheid; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Palo Alto, California • Denver, Colorado • Englewood, Colorado + 8 more

Search by objective public record fields.

A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease

ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings

ALPCO 25(OH) Vitamin D CLIA Kit - Fresh Versus Frozen Serum and Plasma Stability Study

Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer

Analytical and Clinical Performance Testing Plan

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)

Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer

Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer

SARS-CoV-2 OTC At Home Test

ACR | LAB Urine Analysis Test System Evaluation of Performance

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Predicting Endometrial Receptivity for Optimal Reproductive Management

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

EXoPERT EMERALD Clinical Study

Clinical Performance Evaluation of the C2i-Test

Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer

Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer